drugset / Trial / NCT01078389

Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

NCT01078389

Phase 2 Completed 314 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.

Timeline

Start
2010-03
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Febuxostat Small molecule 40 mg Oral
Subject Febuxostat Small molecule 80 mg Oral

Indications

No indication recorded.